John Hastewell served in a series of wide-ranging roles in his nearly 30 years at Novartis. Most recently, he was the head of Novartis Institutes for Biomedical Research (NIBR) Biologics Center where he was responsible for the discovery of antibody, protein, and nucleic acid-based therapeutics. Formerly, he was the global head of the Program Office, where he worked on NIBR’s research strategy and portfolio management and oversaw the company’s strategic focus on building their biologics drug pipeline. Before working at NIBR, John also served in several leadership roles at Novartis based in the UK, including head of Thrombosis Research and leadership of biochemistry and pharmacology, as well as overseeing all respiratory research disease projects to ensure rapid and effective translation to the clinic. He was also head of a strategy team defining the company’s long-term research direction and led the Immunology platform across all Novartis disease areas.
Anna Batarina, CFA
Anna Batarina, a partner at Apple Tree Partners (ATP), has twenty years of experience in international business, capital markets, corporate finance, and strategy. For more than a decade, Anna held positions of increasing responsibility at Uralkali, a leading global agrochemical business, culminating as senior vice president heading Capital Markets and Investor Relations. At Uralkali, Anna implemented best-in-class corporate governane processes, executed a series of industry consolidation transactions, and led one of the most successful IPOs on the London Stock Exchange. Prior to Uralkali, Anna was an associate at A1/Alfa Eco, Russia’s largest private equity firm, and before that was a senior consultant in Financial and International Tax Services at Ernst & Young.
Prior to joining ATP in 2016, Anna worked on the strategy team at the Global Fund to Fight AIDS, Tuberculosis and Malaria. She received an MA in Global Affairs (Global Health track) and a graduate certificate in Global Health and Public Health from Yale University. She holds a master’s degree in Clinical Psychology from Lomonosov Moscow State University, a master’s degree in Finance from Financial University under the government of the Russian Federation, and a CFA charter.
Andrew Bayliffe, PhD
Andrew Bayliffe has more than 20 years of leadership experience in the biopharmaceutical industry with expertise in the discovery and development of both small molecule and antibody therapeutics across a broad range of diseases areas. He joined Apple Tree Partners as a venture partner in 2019 from GlaxoSmithKline (GSK), where he served as head of the Fibrosis and Lung Injury Discovery unit at GSK’s R&D headquarters in Stevenage, UK, and held senior roles in antibody discovery and development in the US and UK.
Andrew is an honorary professor at the Wolfson Institute of Experimental Medicine at Queens College in Belfast. He completed his undergraduate and PhD studies in pharmacology, physiology and molecular biology at Manchester University and Leeds University in the UK.
Raj Chopra, FRCP, FRCPath, FRSB, PhD
Raj Chopra brings to Elstar Therapeutics a wealth of experience in academic medical research, clinical practice, and biopharmaceutical industry leadership, with expertise in hematological oncology, solid tumor biology, transplantation, and cell therapies. He joined Apple Tree Partners as a venture partner in 2020 after serving as director of the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research in London, where he led one of the world’s largest academic drug discovery groups and focused on targeted protein degradation and complex 3D cell culture models. From 2009-2016, Raj was vice president of Translational and Early Drug Development at Celgene, leading an international team of more than 100 scientists. Prior to Celgene, Raj held leadership positions in AstraZeneca’s Oncology Therapeutics group.
Raj trained in medicine at University College London, where he also earned his PhD in medicine, cell and molecular biology. He started his academic career as director of Hematological Oncology at Christie Hospital and was group leader at the Paterson Institute of Cancer Research, both located in Manchester, UK. He is a fellow of the Royal College of Physicians of London, the Royal College of Pathologists, and the Royal Society of Biology. Raj is a co-founder of Monte Rosa Therapeutics, a biotech focused on targeted protein degradation.
Seth Harrison, MD
Seth Harrison, the founder and managing partner of Apple Tree Partners, has invested in life sciences since 1991 and has founded and funded numerous successful biotechnology and medical technology companies. He currently serves as chair of ATP portfolio companies Braeburn Pharmaceuticals, Gala Therapeutics, and Stoke Therapeutics and as a board member for Akero Therapeutics and Nine Square Therapeutics. Some of his prior investments include Aileron Therapeutics, ArQule, Coelacanth, Cyrano Sciences, Gloucester Pharmaceuticals, HeartWare International, Informed Access, SGX Pharmaceuticals, Syntimmune, Tokai Pharmaceuticals, Ultracision, and ViroPharma. From 2002 to 2010, he also served on the board of the International Partnership for Microbicides. Prior to founding ATP in 1999, Seth was a general partner at Oak Investment Partners, and before that a venture partner at Sevin Rosen Funds.
Seth received a BA degree from Princeton University, an MD and MBA both from Columbia University, and completed a surgery internship at New York Presbyterian Hospital.
Joseph A. Yanchik III, JD
Joseph Yanchik has been founding and funding life science companies for more than 20 years. He initially joined ATP in 2005 and rejoined the firm as a venture partner in 2020 after founding and running two of its portfolio companies. In 2005, Joe founded Tokai Pharmaceuticals, a biopharmaceutical company focused on prostate cancer, serving as president and CEO from 2005 to 2008 and then as a director through 2017. Concurrently, Joe founded Aileron Therapeutics, a company focused on developing a novel class of stabilized cell-permeating peptides called stapled peptides, for cancer and other diseases. He established a $1.1 billion partnership between Aileron Therapeutics and Roche Pharmaceuticals and led Aileron from inception to public listing, serving as president, CEO, and director from 2006 to 2018. Previously, Joe served as vice president of corporate development at Mendel Biotechnology, an agricultural biotech company, and founded and served as chief financial officer of Poetic Genetics, a gene therapy company. He began his career practicing corporate and securities law at Cahill Gordon & Reindel, where he specialized in public securities offerings, high-yield debt financings, and M&A. He then moved to Venture Law Group in Menlo Park, where he specialized in financing early-stage life science and technology companies.
Joe received a bachelor’s degree from Loyola College in Maryland and a JD from the Villanova University School of Law, where he was managing editor of the Law Review. He is a member of the New York, California, and District of Columbia bars.